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Automated high throughput analysis of
antiretroviral drugs in dried blood spots
U. Duthaler,a† B. Berger,a† S. Erb,b M. Battegay,b E. Letang,c,d,e S. Gaugler,f
S. Krähenbühla and M. Haschkea,g,h*
For therapeutic drug monitoring in remote settings, dried blood spots (DBS) are particularly advantageous, as blood sample
collection and handling is uncomplicated. The aim of this study was to develop and validate an automated extraction method
for the analysis of nevirapine, efavirenz and lopinavir in DBS samples. Automated extractionwas performedwithmethanol : water
(70 : 30 v/v), using a DBS-MS 500 autosampler coupled to a liquid chromatography tandem mass spectrometry system. The
autosampler used digital images of each DBS to position the extraction head, sprayed 10 μl of internal standard onto each DBS
and extracted a 4-mm disc (Ø) from the centre of each spot by unilateral flow using 25-μl extraction solvent. The analytes were
baseline separated on a pentafluorophenyl column and analysed by using electrospray ionization with multiple reaction
monitoring in positive polarity mode for nevirapine and lopinavir and in negative mode for efavirenz. The method was linear
between 10 and 10000 ng/ml for all analytes. Automated sample extraction resulted in consistent recoveries (nevirapine:
70 ± 6%, efavirenz: 63 ± 11% and lopinavir: 60 ± 10%) and matrix effects between different donors and concentration levels.
Intra-day and inter-day accuracy and precision deviations were ≤15%. Manual and automated extractions of DBS samples
collected within the framework of an adherence assessment study in rural Tanzania showed good agreements with deviations
of less than 10%. Our study highlights that therapeutic drug monitoring samples obtained in the resource-constrained setting
of rural Africa can be reliably determined by automated extraction of DBS. Overall, automatization improved method sensitivity
and facilitates analysis of large sample numbers. Copyright © 2017 John Wiley & Sons, Ltd.
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Introduction
The dried blood spot (DBS) technique facilitates minimally invasive
blood sampling, whereby capillary blood is spotted onto a filter
paper, ideally leading to a homogenous blood spot. After complete
drying, a fixed blood spot area can be punched out for drug
analysis, making exact pipetting unnecessary.[1] In contrast to
conventional plasma sampling, the DBS technique does not require
a trained phlebotomist. Only a few drops of blood are withdrawn
after a simple and minimally invasive finger prick: a process that
can even be performed by adequately instructed patients.[2]
Moreover, DBS samples minimize biohazard risk during further
sample handling and are generally stable at room temperature.[3]
Hence, the collection of DBS samples is especially attractive for field
studies in remote or resource-constrained settings, where
uninterrupted cold chains cannot be guaranteed.[4]
Worldwide, an estimated 37 million people are HIV positive, of
which the majority reside in Sub-Saharan Africa.[5] Antiretroviral
therapy leading to viral suppression has been strongly correlated
with increase in survival and improved quality of life.[6,7] Good
adherence to antiretroviral therapy is paramount, and patients with
suboptimal adherence are at risk of HIV progression and the
development of drug resistance, which consequently narrows
options for future treatment.[6,8] Circulating antiretroviral drug
concentrations are characterized by a high degree of between-
patient variability, due to genetic and nongenetic heterogeneity
in drug disposition. Therapeutic drug monitoring (TDM) is an
approach to standardize drug exposure through dosage
individualization and to prevent both the toxicity associated with
high exposure and the inefficacy associated with insufficient
exposure.[9–12] However, particularly in resource-limited settings,
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TDM is infrequently performed due to technical challenges.[6,8,13] In
such settings, the previously mentioned advantages of DBS
sampling could facilitate implementation of regular TDM.
On the other hand, the development of bioanalytical methods for
DBS samples is more complex than for conventional liquid matrices,
as variable haematocrit values alter not only analyte recovery but
also the extent of blood diffusion within the filter paper, thereby
impacting the reliability of the DBS analysis.[14] Moreover, the small
amount of blood collected on a filter card requires highly sensitive
bioanalytical methods.[14] Finally, concentrations in DBS samples
must be compared with conventional plasma samples to allow
correct interpretation of DBS measurements.[15–18]
The aim of the present work was to develop and validate a fully
automated DBS extraction method for the analysis of nevirapine,
efavirenz and lopinavir, with sufficient robustness to handle large
sample numbers. Certain steps of the validation procedure such
as assessment of extraction recovery and matrix effects are more
complex when automated extraction systems are used and require
modifications of standard validation procedures. Feasibility of the
automated extraction method was demonstrated by comparing
concentrations obtained after automated and manual DBS
extraction of samples from a combination antiretroviral therapy
adherence assessment study conducted at the Chronic Diseases
Clinic of Ifakara, Tanzania. The DBS samples of patients treated with
the non-nucleoside reverse transcriptase inhibitors efavirenz and
nevirapine and the protease inhibitor lopinavir were collected.[19]
In contrast to previous studies that used manual DBS extraction
for the measurement and validation of combination antiretroviral
therapy compounds,[20–23] we extracted DBS by using a fully
automated DBS autosampler (CAMAG, DBS-MS 500).[24] This
autosampler exhibits a TLC-based extraction head, with a circular
plunger that seals a vent of 4-mm inner diameter on the blood spot.
The extraction solvent passes horizontally from the inlet capillary
through the blood spot to the outlet capillary and into a sample
loop (unilateral extraction). Thus, in contrast to other online DBS
extraction systems,[25–28] the extraction solvent is not forced
vertically through the filter paper (flow-through extraction). The
autosampler is connected to a liquid chromatography tandemmass
spectrometry (LC–MS/MS) system, features 500 DBS card slots, takes
an image of the blood spot before and after the extraction process,
sprays the internal standard solution onto each blood spot and
works with a low volume (~25 μl) of extraction solvent.
Materials and methods
Chemicals, reagents, and reference compounds
Gradient grade water and methanol for liquid chromatography as
well as formic acid (98–100%) were purchased from Merck
(Darmstadt, Germany). Dimethyl sulfoxide (DMSO) was obtained
from Sigma-Aldrich (St. Louis, USA). The reference compounds,
nevirapine, efavirenz and lopinavir and its deuterated internal
standards (IS) nevirapine-d3, efavirenz-d5 and lopinavir-d8 were
products of Toronto Research Chemicals (Toronto, Canada). DBS
cards (grade 226 filter paper) were kindly provided by CAMAG
(Muttenz, Switzerland). Fresh whole blood was obtained from the
local blood donation centre (Basel, Switzerland).
LC–MS/MS instrumentation and settings
Chromatography was performed on a modular high-performance
liquid chromatography system from Shimadzu (Kyoto, Japan); it
contained a system controller (CBM-20A), four pumps (2× LC-
20AD and 2× LC-20AD XR), a degasser (DGU-20A5) and a column
oven (CTO-20A). A CTC HTS PAL autosampler (CTC analytics,
Zwingen, Switzerland) was used in the case of manual extraction
of DBS samples. Automated extractions were carried out with a
DBS-MS 500 autosampler (CAMAG, Muttenz, Switzerland). Analytes
were separated on a Kinetex 2.6 μ F5 100 Å (50 × 2.1 mm) analytical
column (Phenomenex, Torrance, USA). A filter frit (SS 0.5 μm
0.62 × 0.65, Ercatech AG, Bern, Switzerland) was connected
upstream to the analytical column. Mobile phase A consisted of
water plus 0.1% formic acid, while methanol supplemented with
0.1% formic acid was used as mobile phase B. The following
stepwise gradient was applied: 5% (0–0.25 min), 5%–60% (0.25–
0.4 min), 60%–80% (0.4–2.0 min), 80%–95% (2.0–2.2 min), 95%
(2.2–3.0 min) and 5% (3.0–3.3 min). The flow rate was set at
0.5 ml/min at 45 °C. The high-performance liquid chromatography
liquid stream was connected to an API 4000 Q-trap tandem mass
spectrometer (AB Sciex, Framingham, MA, USA) only between
minute 0.6 and 2.5 of each run to reduce system contamination.
The analytical run was divided into three multiple reaction
monitoring periods, whereas electrospray ionization was switched
frompositive to negativemode betweenminute 1.3 and 1.7 (period
2) of each run. The following mass transitions and compound
specific settings were used: 267 → 226 m/z for nevirapine
[declustering potential (DP): 76 V, collision energy (CE): 20 V,
entrance potential (EP): 10 V, collision cell exit potential (CXP):
16 V], 270 → 229 m/z for nevirapine-d3 (DP): 121 V, CE: 37 V, EP:
10 V, CXP: 16 V), 314 → 244 m/z for efavirenz (DP: 95 V, CE:
26 V, EP: 10 V, CXP: 13 V), 319 → 248 m/z for efavirenz-d5
(DP: 75 V, CE: 28 V, EP: 1 V, CXP: 15 V), 629→ 155 m/z for
lopinavir (DP: 111 V, CE: 35 V, EP: 10 V, CXP: 10 V) and
637→ 163 m/z for lopinavir-d8 (DP: 66 V, CE: 75 V, EP: 10 V, CXP:
10 V). The general settings of the mass spectrometer were as
follows: ion source gas-1 60 l/min (N2), ion source gas-2 50 l/min
(N2), curtain gas 10 l/min, collision gas 4 l/min, ion spray voltage
5500 V (positive mode) and 4200 V (negative mode) and source
temperature 350 °C. ANALYST software 1.6.2 (AB Sciex, Framingham,
MA, USA) was used to operate the LC–MS/MS system.
Preparation of standards and extraction solvents
Nevirapine, efavirenz and lopinavir stock solutions were prepared in
DMSO (10mg/ml) and stored at20 °C. Stock solutions were pooled
and serially diluted with DMSO to cover a range from 1000 to
1 μg/ml. The dilution series for calibrators andQC samples originated
from different weightings. IS stock solutions were likewise prepared
in DMSO at a final concentration of 1 mg/ml. The extraction solvent
was a mixture of methanol and water (70 : 30 v/v). The IS was
dissolved in methanol at a concentration of 1 μg/ml for nevirapine-
d3 and at 2 μg/ml for efavirenz-d5 and lopinavir-d8.
Preparation of calibration and quality control samples
Freshly collected human blood was obtained from the local blood
donation centre (Basel, Switzerland). Ethylenediaminetetraacetic
acid was used as an anticoagulation agent (vacutainer tubes, BD,
Allschwil, Switzerland). Calibrators and Quality control (QC) samples
were prepared by spiking blank blood with the analyte dilution
series in a ratio of 1 : 100 (v/v). Calibration samples for automated
extractions encompassed a range from 10 to 10000 ng/ml and 50
to 10000 ng/m for manual extractions. QC samples were prepared
at the lower limit of quantification (LLOQ, 10 ng/ml), as well as at
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low (50 ng/ml), medium (500 ng/ml) and high (5000 ng/ml)
concentration levels. In the case of manual extractions, the LLOQ
was set to 50 ng/ml. Spiked blood samples were gently mixed
and agitated on a roll-agitator (CAT RM 5 Staufen, Switzerland), after
which 15-μL aliquots were spotted onto CAMAG DBS cards
(CAMAG, Muttenz, Switzerland). DBS cards were dried at room
temperature for at least 2 h and were subsequently stored at
20 °C in sealed plastic bags containing desiccants. Each
calibration set consisted of 1 blank sample (DBS sample processed
without IS), 1 zero sample (DBS sample processed with IS) and 11
calibrators (9 calibrators in the case of manual extractions).
Calibration lines were established by linear regression of the
nominal analyte concentration against the analyte : IS peak area
ratio by using a weighting factor of 1/x2.
Dried blood spot sample extraction
Automated extraction
The extraction head was cleaned in an ultra sound bath at 40 °C for
10 min prior each set of analyses because filter paper debris can
clog the port after several extractions. Moreover, the internal
standard module was primed for at least 3 cycles to clear air
bubbles from the syringe. Each extraction solvent was primed for
more than 3 cycles, and the rinsing solvents were flushed for
4 min. Twisted DBS cards were pressed overnight under a heavy
weight before use in the autosampler.
The DBS cards were photographedwith the built-in camera of the
DBS-MS 500 autosampler before and after each run to check for the
presence of a blood spot and to adjust the extraction head to the
centre of each spot. The software of the autosampler automatically
recognized inadequate DBS based on their roundness, diameter
and area. Inadequate DBS were excluded from analysis. Ten μl of
internal standard was sprayed in a homogenous layer onto each
spot. After a 20-s drying time, the samples were extracted with a
volume of 25 μl and a 40-μl/min flow rate. As a 20-μl loop was
installed, the first 5 μl of each extraction was discarded. To complete
the automated DBS extraction cycle, the system was first rinsed for
20 s with a methanol : acetonitrile : isopropanol : water
(1 : 1 : 1 : 1 v/v) mixture, after which it was cleaned for a further
20 s with water containing 0.1% formic acid.
Manual extraction
Ten μl of internal standard was sprayed by using the internal
spraying device of the DBS-MS 500 autosampler onto each spot.
The card was left to dry at room temperature, and then a disc of
3 mm in diameter was manually punched out from the centre of
each spot by using a manual hole puncher (Whatman, Sanford,
ME, USA) and transferred to a 0.75-ml autosampler matrix tube
(Thermo Scientific, Reinach, Switzerland). Afterwards, 200-μl
extraction solvent, methanol : water (70 : 30 v/v), was added to each
disc. The samples were mixed for 3 min, centrifuged (30 min;
3220 g; 10 °C, Eppendorf, Hamburg, Germany) and kept at 10 °C
in the autosampler. To perform the analysis, an aliquot of 20-μl
supernatant was injected into the LC–MS/MS system.
Subsequently, the system was washed with methanol and a
methanol : water mixture (1 : 1 v/v).
Method validation
The automated DBS extraction LC–MS/MS method was validated
following the FDA guidance for bioanalytical method validation
for industry.[29] The method was validated in terms of selectivity,
sensitivity, accuracy, precision, linearity, extraction recovery, matrix
effect and analyte stability. In addition, the impact of the applied
blood volume was evaluated during the validation process.
Selectivity and sensitivity
Blank DBS samples from seven different subjects were examined
for interfering endogenous matrix components. The signal at the
designated LLOQ was set to be at least five times higher than the
noise signal, with a bias in precision of less than 20% and accuracy
between 80 and 120%.
Linearity
The coefficients of variation (R2) of the linear regression, between
the analyte peak area, normalized by the internal standard peak
area and the nominal concentration, had to be ≥0.99. At least
75% of the calibration samples had to be within ±15% (LLOQ:
±20%) of the nominal value.
Intra-day and inter-day accuracy and precision experiments
The accuracy and precision of the method were determined by
analysing QC samples from seven different subjects at four
concentration levels (LLOQ, low-level, medium-level and high-level
QC). Placing the QC samples between two calibration lines, one
spot was analysed per condition (n = 28 QC samples, n = 20
calibrators). Precision and accuracy were evaluated within a single
validation run (intra-day) as well as between three runs recorded
on different days (inter-day). The precision was calculated as the
percentage relative standard deviation (CV, %) for each QC
concentration within an analytical run (intra-day precision, n = 7)
and over all three runs (inter-day precision, n = 21). A precision of
<15% (<20% at the LLOQ) was accepted in our study. The accuracy
was assessed from the overall mean of each QC concentration
divided by its nominal value (bias, %). A mean accuracy of 85–
115% (LLOQ: 80–120%) was acceptable; however, at least 67% of
the QC samples of each concentration level had to be within the
acceptance range.
In addition, DBS spots using 15 and 30-μl bloodwere prepared at
LLOQ, low, medium and high concentration levels. The change in
concentration of 15 to 30 μl spots was calculated. A deviation of
≤15% (LLOQ ≤20%) implied that the method does not depend on
the applied volume of blood.
Recovery and matrix effect
The extraction recovery of the DBS-MS 500 autosampler was
investigated for DBS samples of seven different subjects. DBS spots
at 50, 500 and 5000 ng/ml were prepared for the recovery
experiments. Each spot was extracted six times for medium and
high concentration samples (500 and 5000 ng/ml), while low
concentration samples (50 ng/ml) were extracted three times.
Between two extractions, a drying time of approximately 15 min
was programmed. Using the built-in camera of the autosampler,
the extraction head automatically locked onto the same area in
the centre of the blood spot. The recovery was finally estimated
as the percentage ratio of the analyte peak area of the first
extraction to the sum of the peak areas of all subsequently
conducted extractions.
Blank DBS samples from seven different subjects were prepared
to quantify the effect of the blood matrix on the analyte signal
intensity. The extraction solvent was spiked with 10, 100 or 1000-
ng/ml nevirapine, efavirenz and lopinavir. Each blank DBS sample
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and a corresponding card without a blood spot were processed at
each concentration level. The matrix effect was calculated as the
ratio of the analyte peak areas measured, following extraction of
filter cards containing a blank DBS, to the peak areas of filter cards
without matrix.
Stability
Stability tests of nevirapine, efavirenz and lopinavir were performed
under different conditions at a medium concentration level of
500 ng/ml. Stability was evaluated in the fridge (4 °C) and the
freezer (20 °C) after 4 weeks of storage. Five replicates were
analysed per condition and compared with a set of QC samples,
prepared on the day of analysis.
Method application
Clinical application of the LC–MS/MSmethodwas demonstrated by
analysing a series of randomly selected DBS samples. The DBS
samples contained nevirapine, efavirenz and lopinavir and were
collected during an adherence assessment study conducted in
Tanzania.[19] Ethical approval was obtained from the Institutional
Review Board of the Ifakara Health Institute (reference no IHI 28-
2013), the Tanzanian National Institute of Medical Research, Dar
es Salaam, Tanzania (reference no NIMR/HQ/R.8a/V01. IX/I762)
and the Tanzanian Commission for Science and Technology (no
2014-276-NA-2014-195). For each analyte, 30 DBS samples were
Figure 1. Chromatograms of blank DBS samples (n = 7 donors) were
placed next to an LLOQ (10 ng/ml) sample. The method is selective for the
quantification of nevirapine, efavirenz and lopinavir in DBS samples.
[Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2. Optimization of the extraction parameters for the automated analysis of nevirapine, efavirenz and lopinavir fromDBS samples. High concentration
QC samples (n = 4) were extracted for each condition. Effect of the methanol : water mixture, extraction volume and extraction flow on the extraction yield
was evaluated. Conditions with grey-coloured box plots were selected for the final extraction method. The percent figures above the boxes are CV%.
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processed by automated and manual extraction. In both cases, the
IS was sprayed onto the DBS. Bland–Altman plots were createdwith
GRAPHPAD PRISM 6.04 (La Jolla, CA, USA) to compare the two extraction
methods.[30] Mean-difference plots were generated by using the
mean %difference bias [%difference = (concentration automated
extraction  concentration manual extraction/mean
concentration) • 100] and the 95% limits of agreement (±2 standard
deviations). At least 67% of the samples had to be within ±20%
limits according to cross-validation guidelines.[31,32]
Results and discussion
Method development
Assessment of adherence to antiretroviral therapy is essential to
assure sufficient viral suppression and improve survival and quality
of life in HIV-infected patients. While adherence in industrialized
nations where TDM belongs to the standard of care generally is
high, less is known about adherence to antiretroviral treatment in
resource-limited countries. In such settings, the advantages of
DBS samples could facilitate monitoring of antiretroviral therapy.
Importantly, it has been demonstrated that antiretroviral drugs
can be analysed in DBS samples, and moreover, a good correlation
between plasma and DBS concentrations has been found for
efavirenz and nevirapine.[20–23,33,34] However, compared with
conventional plasma or serum samples, working with DBS samples
entails several method-specific drawbacks. The preparation of
calibrator and QC samples, as well as the extraction procedure, is
more laborious. Moreover, the small amount of blood available in
the DBS sample is a challenge and requires development of
particularly sensitive methods. Here, we demonstrate that these
challenges can, at least, in part, be overcome for the analysis of
nevirapine, efavirenz and lopinavir by using a DBS autosampler
system.
In the first stage of method development, mass spectrometer
voltages were adjusted to maximize the peak response of the
parent mass and the product ions for each compound. The best
results were obtained by using the transitions 267 → 226 m/z,
314→ 244 m/z and 629→ 155 m/z for nevirapine, efavirenz and
lopinavir, respectively. Similar transitions were used for the internal
standards, with the addition of the respective amount of deuterium
atoms (nevirapine-d3: 270→ 229m/z, efavirenz-d5: 319→ 248m/z,
lopinavir-d8: 637 → 163 m/z). The same MS/MS transitions were
also used in other published LC–MS/MS methods.[20,21,23,33]
Nevirapine and lopinavir were optimized in positive ionization
mode, while efavirenz was optimized in negative ionization mode.
Therefore, efavirenz had to be chromatographically separated from
nevirapine and lopinavir, as negative and positive ionizationmodes
cannot be run in parallel with the employed mass spectrometer.
Figure 1 illustrates that baseline separation of all analytes was
Table 1. Intra-day and inter-day accuracy and precision of nevirapine, efavirenz and lopinavir (10–10 000 ng/ml)
Analyte Intra-day Inter-day
Day 1 Day 2 Day 3 Day 1–3
QC level Conc. found at Accuracy ± CV Conc. found at Accuracy ± CV Conc. found at Accuracy ± CV Conc. found at Accuracy ± CV
[ng/ml] [ng/ml] [%] [ng/ml] [%] [ng/ml] [%] [ng/ml] [%]
Nevirapine 10 9.4 94.1 ± 7.6 10.8 108.4 ± 6.8 10.8 107.9 ± 8.6 10.3 103.4 ± 9.8
50 44.5 88.9 ± 8.1 47.5 95 ± 13.9 47.9 95.7 ± 6.7 46.6 93.2 ± 10.2
500 470 93.9 ± 5.2 466 93.3 ± 4.7 481 96.1 ± 6.8 472 94.4 ± 5.5
5000 4750 95 ± 7.4 4680 93.6 ± 5.4 4923 98.5 ± 9.9 4784 95.7 ± 7.8
Efavirenz 10 9.2 92.4 ± 8.1 9.5 95.2 ± 14.5 10.6 105.7 ± 10.4 9.8 97.8 ± 12.3
50 46.7 93.5 ± 8.6 47.1 94.2 ± 11.5 49.6 99.2 ± 9.2 47.8 95.6 ± 9.7
500 479 95.9 ± 5.2 475 94.9 ± 4.6 489 97.7 ± 6.6 481 96.2 ± 5.4
5000 4767 95.3 ± 8.4 4593 91.9 ± 8 4861 97.2 ± 9 4741 94.8 ± 8.4
Lopinavir 10 9.7 96.8 ± 6.2 10.0 99.7 ± 12 10.9 109.3 ± 8.5 10.2 101.9 ± 10.3
50 46.2 92.4 ± 10.3 45.8 91.5 ± 13.3 47.0 94.1 ± 10.1 46.3 92.7 ± 10.8
500 486 97.2 ± 6.9 453 90.6 ± 6.3 461 92.2 ± 7.2 467 93.3 ± 7.2
5000 4757 95.1 ± 9.4 4474 89.5 ± 8.9 4583 91.7 ± 12.2 4605 92.1 ± 10.1
Table 2. Deviation between DBS samples using 15 or 30-μl blood spot volume
Qc level
[ng/ml]
Nevirapine Efavirenz Lopinavir
Concentration found at [ng/ml] Concentration found at [ng/ml] Concentration found at [ng/ml]
— 15 μl 30 μl Change [%] 15 μl 30 μl Change [%] 15 μl 30 μl Change [%]
10 9.4 9.5 0.7 9.2 9.7 5.1 9.7 9.5 1.7
50 44.5 44.8 0.6 46.7 45.1 3.4 46.2 43.2 6.5
500 470 479 2.0 479 478 0.2 486 455 6.4
5000 4750 4986 5.0 4767 4790 0.5 4757 4710 1.0
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efficiently achieved within a 3-min run time, using a core-shell
pentafluorophenyl phase column. Peak symmetry was satisfactory
using methanol and water supplemented with formic acid (0.1%)
as mobile phase.
Further method development focused on improving the
automated extraction process where the main adjustable
instrument parameters are the amount of IS sprayed onto the
DBS, as well as the extraction flow, extraction volume and
extraction solvent composition. Parameters giving the highest
signal intensities, best precisions and optimal peak shapes were
selected (Fig. 2). First, different methanol : water mixtures (50 : 50,
60 : 40, 70 : 30, 80 : 20 and 90 : 10 v/v) were tested. A high water
amount increased the risk of clogging the extraction head, as
presumably more biomolecules and cellular components are
removed from the DBS. Robustness of the extraction was thereby
limited. Overall, a mixture of 70 : 30 methanol : water resulted in
the highest signal intensities and best precision. Peak symmetry
was disturbed by methanol concentrations exceeding 80% in the
extraction solvent. Replacing methanol with acetonitrile did not
improve extraction yield andworsened peak shapes. The extraction
volume was increased stepwise from 20 to 70 μl (20, 25, 30, 40, 50,
60 and 70 μl), while the last 20 μl of each extractionwere trapped in
the sample loop. Signal intensities decreased with larger extraction
volumes to about 80–90% of the initial value. Almost 50% is
extracted within the first 10 μl of the extraction fraction. An
extraction volume of 25 μl was selected because the precision
was enhanced compared with 20 μl, and the signal intensity was
only marginally lower. As extraction flow did not seem to have a
significant impact, the standard setting of 40-μl/min flow was used
to perform automated extraction. The wash cycle was optimized in
order to reduce analyte carry-over. The signal in a blank sample
after injection of the highest calibrator was ten times lower than
the signal detected at LLOQ. Hence, carry-over of the automated
extraction of the analytes is negligible.
Method validation
Selectivity and sensitivity
Selectivity of the method was tested for interfering matrix
components in seven blank human DBS samples (Fig. 1). Noise level
baselines of the blank samples did not show coeluting peaks at the
retention time of nevirapine (1.1 min), efavirenz (1.5 min) or
lopinavir (1.9 min). Moreover, internal standards that were sprayed
onto blank DBS spots did not cause interfering signals. Hence, the
developed method is selective for the analysis of the investigated
antiretrovirals.
A sensitivity of 10 ng/ml was achieved for all analytes. Based
on published data, we expect this quantification limit to be
sufficient to perform therapeutic monitoring of nevirapine,
efavirenz and lopinavir.[35] Figure 1 illustrates that the signal
intensity at LLOQ is at least five times higher than the
background noise level.
Linearity
Linearity was attained over a calibration range of 10 to
10000 ng/ml for all analytes. Taking all validation experiments into
account, the coefficient of variation (R2) was always >0.99 for each
Figure 3. (a) Pictures of DBS before and after six consecutive extractions.
Using the built-in camera of the autosampler, the extraction head
automatically locked on the same position in the centre of the blood spot.
(b) Extraction recovery of nevirapine, efavirenz and lopinavir determined at
low, medium and high concentrations of four different donors. Decrease in
peak area after six (medium and high QC) or three (low QC) repetitive
extractions is shown. Recoveries were consistent between different subjects
and over different concentrations. Bold numbers are recoveries +/ CV%.
Table 3. Matrix effect (ME) of nevirapine, efavirenz and lopinavir in DBS samples
Concentration Nevirapine Efavirenz Lopinavir
ME ± CV [%] Mean ± CV [%] ME ± CV [%] Mean ± CV [%] ME ± CV [%] Mean ± CV [%]
10 ng/ml 92.2 ± 1.0 92.0 ± 0.4 52.7 ± 4.9 54.8 ± 10.4 100.6 ± 2.0 94 ± 6.2
100 ng/ml 91.5 ± 1.8 — 50.4 ± 5.4 — 91.5 ± 2.0 —
1000 ng/ml 92.1 ± 3.4 — 61.2 ± 11.0 — 89.7 ± 2.0 —
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analyte. The upper limit of quantification also encompasses high
therapeutic through concentrations.[11,12,36,37] This is especially
important for the automated extraction of DBS, as dilution of the
DBS samples cannot be easily performed. Thus, clinically occurring
concentrations can be quantified by linear regression within the
chosen calibration range.
Accuracy and precision
Intra-day and inter-day accuracy and precision data are
summarized in Table 1. QC samples were derived from seven
donors. Intra-day precisions of less than 13.9%, 14.5% and
13.3% were found for nevirapine, efavirenz and lopinavir
respectively. Mean intra-day accuracies were between 88.9 and
108.4% for nevirapine, 91.9 and 105.7% for efavirenz and 90.6
and 109.3% for lopinavir. Inter-day precisions were ≤12.3% for
all three analytes. On all occasions, not more than two out of
the seven QC samples per concentration were outside the 85–
115% (LLOQ: 80–120%) limits.
In addition, concentrations of QC samples differed by less than
6.5% when 30 μl instead of 15 μl of blood was spotted onto cards
(Table 2). Hence, the applied blood volume produced reproducible,
volume-dependent spot areas and therefore did not affect accuracy
and precision of the analysis. Overall, the results were consistent
with conditions specified by regulatory guidelines.[29]
Recovery and matrix effect
The relative recovery and matrix effect was determined in four
different donors at low, medium and high QC levels (Fig. 3). In
addition, the recovery of the analytes was assessed by using
aqueous analyte solutions spotted onto the filter paper (‘dried
water spots’). The highest mean recovery was achieved for
nevirapine with 70%, followed by efavirenz (63%) and lopinavir
(60%). A bias in recovery of less than 7.2%was determined between
subjects, indicating high consistency in the sample extraction
process. Recovery at low concentration was overestimated by
approximately 10% compared with medium and high
concentration samples, as the limit of quantification was already
reached after three instead of six consecutive extractions. The
recovery of dried water spots was>97%, indicating that blood acts
as an extraction barrier.
The signal intensity of nevirapine and lopinavir was only
suppressed by the DBS matrix by about 8% and 6% respectively
(Table 3). However, a significant suppressive matrix effect was
observed for efavirenz, where the signal was reduced to
approximately 50% due to the biological matrix. Importantly, the
matrix effect was independent of concentration, as its deviation
was ≤10.4% over the tested concentration range and it did not vary
between subjects (CV ≤ 11.0%). Hence, the matrix of different
donors did not alter the reliability of themethod. Online solid phase
purification of DBS extracts, via column switching or by more
thorough separation of efavirenz and blood ingredients, may
eliminate suppressive matrix effects.[38,39] In summary, the
automated extraction was reproducible and delivered consistent
matrix effects.
Table 4. Stability of nevirapine, efavirenz and lopinavir evaluated under different conditions. DBS samples at a concentration of 500 ng/ml were used
Condition Nevirapine Efavirenz Lopinavir
Concentration
[ng/ml]
Accuracy ±
CV [%]
Change in
concentration
[%]
Concentration
[ng/ml]
Accuracy ±
CV [%]
Change in
concentration
[%]
Concentration
[ng/ml]
Accuracy ±
CV [%]
Change in
concentration
[%]
RT 519.5 103.9 ± 3.6 — 481.6 96.3 ± 6.1 — 532.7 106.5 ± 3.3 —
4 weeks, 4 °C 532.4 106.5 ± 7.3 2.5 511.1 102.2 ± 8.8 6.1 537.2 107.4 ± 8.2 0.8
4 weeks,20 °C 517.4 103.5 ± 7.2 0.4 477.7 95.5 ± 8.2 0.8 559.2 111.8 ± 6.7 5.0
Figure 4. Bland–Altman plots of nevirapine, efavirenz and lopinavir were
generated for automated and manual DBS extractions. Values were
coloured grey if the %difference of the two extraction methods was less
than ±20%; otherwise, values were coloured white. The white plot area
illustrates the 95% limits of agreement. The black dashed line describes
the mean percentage difference between automated and manual
extraction.
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Stability
Stability data are summarized in Table 4. The data implied that
analytes were stable in DBS for 4 weeks at 20 °C or 4 °C, as the
change in concentration compared with a freshly prepared DBS
sample was less than 6.1%. These results are in line with stability
data published in previous studies.[23,33,40,41] Therefore, DBS
samples containing nevirapine, efavirenz and lopinavir are not
likely to be degraded by storage in the fridge for 1 month.
Method application
Ninety DBS samples (30 DBS per analyte) collected in the
framework of a drug adherence study in Ifakara (Tanzania) were
analysed after manual extraction as well as after automated
extraction using the DBS-MS 500 autosampler. Nevirapine
concentrations in DBS were between 3360 and 10800 ng/ml,
efavirenz concentrations were between 262 and 10 200 ng/ml,
and lopinavir concentrations were between 41.8 and 8800 ng/ml;
thus, the selected calibration range was suitable for the
quantification of the collected TDM samples. Sample dilution was
therefore not necessary, which is relevant because it cannot be
easily performed through automated extraction.
Overall, the results obtained after automated and manual
extractions were in good agreement (Fig. 4). The mean bias of
automated to manual extractions was 10.5% for nevirapine,
8.9% for efavirenz and 3.0% for lopinavir. Ninety-five per cent
limits of agreement were narrow with a range of about ±25%
(nevirapine: 32.3 to +11.3%; efavirenz: 38.1% to +20.4%;
lopinavir: 24.7% to +18.8%). Consequently, when comparing
automated and manually extracted samples, 70% or more of the
respective samples showed a deviation of less than 20%, according
to cross-validation guidelines.[31,32] No concentration-dependent
trend was observed between the ratios of the two extraction
methods across the entire concentration range. Overall, automated
extraction was five times more sensitive than manual extraction,
which is mainly due to DBS being extracted with less solvent
through the automated sample workup (25 vs 150 μl) resulting in
more concentrated samples. Both extraction procedures achieved
similar results, and the data obtained were in agreement with afore
mentioned criteria.[31] A thorough clinical validation including the
comparison of plasma and DBS samples will be published
elsewhere.
Conclusions
We developed and validated an innovative LC–MS/MS method by
using on-line DBS extraction for the quantification of three
frequently used antiretroviral drugs. The short time of
approximately 3 min to extract and analyse one DBS sample makes
the method suitable for handling larger sample loads. Automated
DBS extraction entails specific challenges regarding method
validation and requires novel approaches to assess, e.g. extraction
recovery and matrix effects. The calculated interindividual
recoveries and matrix effects were very consistent, and validation
parameters were in accordance with regulatory guidelines. The
method was successfully applied to analyse TDM samples from a
field study. The results obtained by automated and manual
extraction were comparable; however, sample processing time
and method sensitivity were improved by the automated
extraction procedure. Nevertheless, a comprehensive clinical
validation comparing DBS with plasma samples is required before
the developed method can be implemented for TDM in daily
practice.
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